New horizons in tumor microenvironment biology: challenges and opportunities F Chen, X Zhuang, L Lin, P Yu, Y Wang, Y Shi, G Hu, Y Sun BMC medicine 13, 1-14, 2015 | 775 | 2015 |
Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species J Su, X Chen, Y Huang, W Li, J Li, K Cao, G Cao, L Zhang, F Li, ... Cell Death & Differentiation 21 (3), 388-396, 2014 | 271 | 2014 |
TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2+ neutrophils PF Yu, Y Huang, YY Han, LY Lin, WH Sun, AB Rabson, Y Wang, YF Shi Oncogene 36 (4), 482-490, 2017 | 232 | 2017 |
TGF-β promotes immune responses in the presence of mesenchymal stem cells C Xu, P Yu, X Han, L Du, J Gan, Y Wang, Y Shi The Journal of Immunology 192 (1), 103-109, 2014 | 140 | 2014 |
An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles A Ortiz, J Gui, F Zahedi, P Yu, C Cho, S Bhattacharya, CJ Carbone, Q Yu, ... Cancer cell 35 (1), 33-45. e6, 2019 | 139 | 2019 |
miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2 C Xu, G Ren, G Cao, Q Chen, P Shou, C Zheng, L Du, X Han, M Jiang, ... Journal of Biological Chemistry 288 (16), 11074-11079, 2013 | 106 | 2013 |
Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities LY Lin, LM Du, K Cao, Y Huang, PF Yu, LY Zhang, FY Li, Y Wang, YF Shi Oncogene 35 (46), 6038-6042, 2016 | 84 | 2016 |
Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis PF Yu, Y Huang, CL Xu, LY Lin, YY Han, WH Sun, GH Hu, AB Rabson, ... Oncogene 36 (6), 840-849, 2017 | 81 | 2017 |
p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation Y Huang, P Yu, W Li, G Ren, AI Roberts, W Cao, X Zhang, J Su, X Chen, ... Oncogene 33 (29), 3830-3838, 2014 | 74 | 2014 |
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models ES Lightcap, P Yu, S Grossman, K Song, M Khattar, K Xega, X He, ... Science translational medicine 13 (611), eaba7791, 2021 | 69 | 2021 |
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors H Zhang, P Yu, VS Tomar, X Chen, MJ Atherton, Z Lu, HG Zhang, S Li, ... Nature cancer 3 (7), 808-820, 2022 | 35 | 2022 |
Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies Z Lu, A Ortiz, II Verginadis, AR Peck, F Zahedi, C Cho, P Yu, RM DeRita, ... The Journal of Clinical Investigation 131 (10), 2021 | 18 | 2021 |
Mapping and modeling human colorectal carcinoma interactions with the tumor microenvironment N Li, Q Zhu, Y Tian, KJ Ahn, X Wang, Z Cramer, J Jou, IW Folkert, P Yu, ... Nature Communications 14 (1), 7915, 2023 | 11 | 2023 |
Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer Z Lu, J Chen, P Yu, MJ Atherton, J Gui, VS Tomar, JD Middleton, ... Nature communications 13 (1), 6623, 2022 | 11 | 2022 |
Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers O Odnokoz, P Yu, AR Peck, Y Sun, AJ Kovatich, JA Hooke, H Hu, ... Cancer biology & therapy 21 (7), 629-636, 2020 | 11 | 2020 |
Tumor-suppressive and immune-stimulating roles of cholesterol 25-hydroxylase in pancreatic cancer cells N McBrearty, C Cho, J Chen, F Zahedi, AR Peck, E Radaelli, ... Molecular Cancer Research 21 (3), 228-239, 2023 | 10 | 2023 |
RALDH1 inhibition shows immunotherapeutic efficacy in hepatocellular carcinoma P Yu, S Cao, SM Yang, G Rai, NJ Martinez, A Yasgar, AV Zakharov, ... Cancer Immunology Research 12 (2), 180-194, 2024 | 1 | 2024 |